ACUTE-PHASE EFFICACY IN A PHASE 3 MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ZS-9 FOR HYPERKALAEMIA

被引：0
|
作者：
El-Shahawy, Mohamed A. [1 ]
Rasmussen, Henrik S. [2 ]
Lavin, Philip T. [3 ]
Yang, Alex [4 ]
Packham, David K. [5 ]
机构：
[1] Acad Med Res Inst, Los Angeles, CA USA
[2] ZS Pharma Inc, Coppell, TX USA
[3] Boston Biostat Res Fdn, Framingham, MA USA
[4] Xelay Acumen Inc, Belmont, CA USA
[5] Melbourne Renal Res Grp, Melbourne, Vic, Australia
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2014年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP320
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
    Elkins, Jacob
    Veltkamp, Roland
    Montaner, Joan
    Johnston, S. Claiborne
    Singhal, Aneesh B.
    Becker, Kyra
    Lansberg, Maarten G.
    Tang, Weihua
    Chang, Ih
    Muralidharan, Kumar
    Gheuens, Sarah
    Mehta, Lahar
    Elkind, Mitchell S. V.
    LANCET NEUROLOGY, 2017, 16 (03): : 217 - 226
  • [22] Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial
    Peter-Derex, Laure
    Philippeau, Frederic
    Garnier, Pierre
    Andre-Obadia, Nathalie
    Boulogne, Sebastien
    Catenoix, Helene
    Convers, Philippe
    Mazzola, Laure
    Gouttard, Michel
    Esteban, Maud
    Fontaine, Julia
    Mechtouff, Laura
    Ong, Elodie
    Cho, Tae-Hee
    Nighoghossian, Norbert
    Perreton, Nathalie
    Termoz, Anne
    Haesebaert, Julie
    Schott, Anne-Marie
    Rabilloud, Muriel
    Pivot, Christine
    Dhelens, Carole
    Filip, Andrea
    Berthezene, Yves
    Rheims, Sylvain
    Boutitie, Florent
    Derex, Laurent
    LANCET NEUROLOGY, 2022, 21 (09): : 781 - 791
  • [23] Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
    Ruperto, Nicolino
    Brunner, Hermine, I
    Synoverska, Olga
    Ting, Tracy, V
    Mendoza, Carlos Abud
    Spindler, Alberto
    Vyzhga, Yulia
    Marzan, Katherine
    Grebenkina, Lyudmila
    Tirosh, Irit
    Imundo, Lisa
    Jerath, Rita
    Kingsbury, Daniel J.
    Sozeri, Betul
    Vora, Sheetal S.
    Prahalad, Sampath
    Zholobova, Elena
    Aviel, Yonatan Butbul
    Chasnyk, Vyacheslav
    Lerman, Melissa
    Nanda, Kabita
    Schmeling, Heinrike
    Tory, Heather
    Uziel, Yosef
    Viola, Diego O.
    Posner, Holly B.
    Kanik, Keith S.
    Wouters, Ann
    Chang, Cheng
    Zhang, Richard
    Lazariciu, Irina
    Hsu, Ming-Ann
    Suehiro, Ricardo M.
    Martini, Alberto
    Lovell, Daniel J.
    LANCET, 2021, 398 (10315): : 1984 - 1996
  • [24] Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial
    Leere, Julius Simoni
    Karmisholt, Jesper
    Robaczyk, Maciej
    Lykkeboe, Simon
    Handberg, Aase
    Steinkohl, Emilie
    Frokjaer, Jens Brondum
    Vestergaard, Peter
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (05): : 407 - 417
  • [25] Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
    Croop, Robert
    Goadsby, Peter J.
    Stock, David A.
    Conway, Charles M.
    Forshaw, Micaela
    Stock, Elyse G.
    Coric, Vladimir
    Lipton, Richard B.
    LANCET, 2019, 394 (10200): : 737 - 745
  • [26] Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
    Cid, Maria C.
    Unizony, Sebastian H.
    Blockmans, Daniel
    Brouwer, Elisabeth
    Dagna, Lorenzo
    Dasgupta, Bhaskar
    Hellmich, Bernhard
    Molloy, Eamonn
    Salvarani, Carlo
    Trapnell, Bruce C.
    Warrington, Kenneth J.
    Wicks, Ian
    Samant, Manoj
    Zhou, Teresa
    Pupim, Lara
    Paolini, John F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 653 - 661
  • [27] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Gruenwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Urbanowitz, Gladys
    Berg, William J.
    Kay, Andrea
    Lebwohl, David
    Ravaud, Alain
    LANCET, 2008, 372 (9637): : 449 - 456
  • [28] Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial
    Sakaida, Isao
    Kawazoe, Seiji
    Kajimura, Kozo
    Saito, Takafumi
    Okuse, Chiaki
    Takaguchi, Koichi
    Okada, Mitsuru
    Okita, Kiwamu
    HEPATOLOGY RESEARCH, 2014, 44 (01) : 73 - 82
  • [29] Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
    Ramanan, Athimalaipet, V
    Quartier, Pierre
    Okamoto, Nami
    Foeldvari, Ivan
    Spindler, Alberto
    Fingerhutova, Sarka
    Anton, Jordi
    Wang, Zhongkai
    Meszaros, Gabriella
    Araujo, Joana
    Liao, Ran
    Keller, Stuart
    LANCET, 2023, 402 (10401): : 555 - 570
  • [30] Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Gouni-Berthold, Ioanna
    Alexander, Veronica J.
    Yang, Qingqing
    Hurh, Eunju
    Steinhagen-Thiessen, Elisabeth
    Moriarty, Patrick M.
    Hughes, Stephen G.
    Gaudet, Daniel
    Hegele, Robert A.
    O'Dea, Louis St L.
    Stroes, Erik S. G.
    Tsimikas, Sotirios
    Witztum, Joseph L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (05): : 264 - 275
12345